CytRx Corporation (Nasdaq:CYTR) plans to present favorable results from CYTRs Phase 1b/2 clinical trial with aldoxorubicin (formerly INNO-206) in patients with advanced soft tissue sarcoma will be featured in a poster and discussion presentation at the Connective Tissue Oncology Society (CTOS) 17th Annual Meeting on November 15 in Prague, Czech Republic.
The abstract, Aldoxorubicin (INNO-206) is an active-drug for the treatment of relapsed or refractory soft tissue sarcomas, will be presented by the clinical trials principal investigator Dr. Sant Chawla, M.D., F.R.A.C.P. Dr. Chawla, a world renowned expert in the treatment of soft tissue sarcomas, is Director of the Sarcoma Oncology Center in Santa Monica, Calif.
Crown Equity Holdings Inc., (OTCPK:CRWE) offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.
Advertising on the Internet is much more cost-efficient than using traditional mass market and niche media. Internet ads can be viewed by millions of people while being displayed all day and night, while television or radio ads generally last less than two minutes and are shown a limited number of times per day.
CRWEs advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.
CRWEs division CRWE AD-Services (www.crwe-adservices.com), is a full service multimedia advertising company specializing in internet marketing. It provides modern and unique advertising campaigns, dedicated to offering the most cost effective advertising solutions.
More about CRWE at www.crownequityholdings.com.
Raptor Pharmaceutical Corp. (Nasdaq:RPTP), reported that Craig B. Langman, M.D., Head of Kidney Diseases, and the Isaac A. Abt, M.D., Professor of Kidney Diseases and Tenured Professor of Pediatrics, Northwestern University Feinberg School of Medicine, will present a Late Breaking Poster session titled "Extended Treatment with RP103 (PROCYSBI(NYSE:TM)) in Patients with Nephropathic Cystinosis" at Kidney Week 2012, the world's premier nephrology meeting, which is being held October 30-November 4th at the San Diego Convention Center in San Diego, California.
Dr. Langman's presentation is on Saturday, November 3rd in a session beginning at 10:00 A.M. PT.
Western Refining, Inc. (NYSE:WNR) reported that on October 16, 2012, its Board of Directors approved a cash dividend of $0.08 per share of common stock for the fourth quarter of 2012.
The dividend will be paid on November 9, 2012, to shareholders of record at the close of market on October 26, 2012.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: CRWENews.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. (Read Full Disclaimer at http://CRWENews.com/disclaimer)
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.